Print this article

Evolution never stops in the pharma industry

Abstract

As all of our interviewed partners confirm, face-to-face meetings are still essential to succeed in the pharmaceutical and chemical business. DCAT is one of the high level events, where the pharma and chemical world meets mid-March every year.
The pharmaceutical industry is again undergoing substantial changes towards personalized medicines, new kinds of therapies and new types of products and hence production processes. Overall, the providers in the pharmaceutical supply chain enjoy growing business due to a number of factors like a swing back of outsourcing business to the West and a steady number of New Drug Applications by the US FDA.
Highest market growth can be seen in the fields of oncology, antivirals, diabetes and other metabolic diseases and immunosuppressants. The USA will remain the most important market by value, while China is growing as the largest market for volumes, mainly in generics. These developments impose a number of challenges to the pharmaceutical supply chain. In this article, we discuss various ways how providers can participate in market growth via different strategies depending on company size, location, know-how and so-called „soft skills“. According to the IMS Institute for Healthcare Informatics, the global pharmaceutical market will reach 1.3 Trillion US$ by 2018.


Roger La force ROGER LAFORCE
Founder and Managing Director of LaForce
Business Solutions LLC, Switzerland

THE AUTHOR:
Longstanding experience in the field of Contract Manufacturing for the pharmaceutical industry, in depth knowledge of the dynamics of this market segment, in the development and launch of generic APIs and